Eyestem to Start Human Trials for Its Pioneering Dry AMD Treatment
03rd April 2024: Eyestem, a cell therapy company at the forefront of regenerative therapy, has received approval from India’s Central Drugs Standards Control Organisation (CDSCO) to commence human trials for Eyecyte RPE™, aimed at combating geographic atrophy arising from dry age-related macular degeneration (AMD). “The commencement of human trials represents a significant and proud moment for all of us at Eyestem,” stated Dr. Jogin Desai, […]
Eyestem to Start Human Trials for Its Pioneering Dry AMD Treatment Read More »
